- Home
- PCB vs ACIU Comparison
PCB vs ACIU Comparison
Compare PCB & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCB
- ACIU
- Stock Information
- Founded
- PCB 2003
- ACIU 2003
- Country
- PCB United States
- ACIU Switzerland
- Employees
- PCB N/A
- ACIU N/A
- Industry
- PCB Major Banks
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- PCB Finance
- ACIU Health Care
- Exchange
- PCB Nasdaq
- ACIU Nasdaq
- Market Cap
- PCB 297.9M
- ACIU 189.1M
- IPO Year
- PCB N/A
- ACIU 2016
- Fundamental
- Price
- PCB $22.36
- ACIU $2.07
- Analyst Decision
- PCB Hold
- ACIU Strong Buy
- Analyst Count
- PCB 2
- ACIU 1
- Target Price
- PCB $22.00
- ACIU $12.00
- AVG Volume (30 Days)
- PCB 35.3K
- ACIU 139.5K
- Earning Date
- PCB 07-24-2025
- ACIU 08-05-2025
- Dividend Yield
- PCB 3.65%
- ACIU N/A
- EPS Growth
- PCB 11.00
- ACIU N/A
- EPS
- PCB 1.94
- ACIU N/A
- Revenue
- PCB $98,720,000.00
- ACIU $32,014,254.00
- Revenue This Year
- PCB $20.01
- ACIU N/A
- Revenue Next Year
- PCB $9.23
- ACIU $533.21
- P/E Ratio
- PCB $11.29
- ACIU N/A
- Revenue Growth
- PCB 5.07
- ACIU 91.20
- 52 Week Low
- PCB $15.03
- ACIU $1.43
- 52 Week High
- PCB $22.37
- ACIU $4.26
- Technical
- Relative Strength Index (RSI)
- PCB 73.19
- ACIU 56.20
- Support Level
- PCB $20.76
- ACIU $1.65
- Resistance Level
- PCB $21.17
- ACIU $2.17
- Average True Range (ATR)
- PCB 0.48
- ACIU 0.17
- MACD
- PCB 0.20
- ACIU -0.01
- Stochastic Oscillator
- PCB 99.27
- ACIU 70.37
About PCB PCB Bancorp
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.